PRSO 10-K & 10-Q changes, risk factors and insider trading
Peraso Inc. · Nasdaq · Semiconductors & Related Devices · CIK 890394 · All filings on SEC.gov
At a glance
What changed in the latest 10-K
Risk Factors
New heading “Our evaluation of strategic alternatives, including Mobix Labs’ proposal, may not result in a transaction or increased value for our stockholders and could create business disruption and stock price volatility.”
Removed heading “Our reduction in force undertaken to significantly reduce our ongoing operating expenses may not result in our intended outcomes and may yield unintended consequences and additional costs.”
Removed heading “Failure to comply with laws relating to employment could subject us to penalties and other adverse consequences.”
Removed heading “The effective increase in the number of shares of our common stock available for issuance as a result of our reverse stock split could result in further dilution to our existing stockholders and have antitakeover implications.”
Largest changes
“We are subject to various employment-related laws in the jurisdictions in which our employees are based. We face risks if we fail to comply with applicable U.S. federal or state employment and wage laws, or employment wage laws applicable to our employees located in Canada. The Reductions create an additional risk of claims being made on behalf of affected employees. Recently, the Company has received and, may in the future receive, claims made on behalf of employees, whom were part of the Reductions, regarding statutory and common law severance payments. …”see in full comparison
“Failure to comply with laws relating to employment could subject us to penalties and other adverse consequences.”see in full comparison
“Trade disputes, trade restrictions, tariffs and other political tensions between the U.S. and other countries may also exacerbate unfavorable macroeconomic conditions including inflationary pressures, foreign exchange volatility, financial market instability, and economic recessions or downturns, which may also negatively impact customer demand for our products or services, delay purchases or renewals, limit expansion opportunities with customers, limit our access to capital, or otherwise negatively impact our business and operations. …”see in full comparison
“On March 3, 2025, the President of the United States announced the imposition of new tariffs on imports from Mexico and Canada, to take effect on March 4, 2025. Effective at 12.01 a.m. ET on March 4, 2025, all goods arriving at U.S. ports and originating from Canada or Mexico are subject to 25 percent tariffs, with some exceptions. Effective February 4, 2025, all goods presented for entry at U.S. ports and originating from China, including Hong Kong, are subject to a 10 percent tariff on Chinese imports. …”see in full comparison
“The effective increase in the number of shares of our common stock available for issuance as a result of our reverse stock split could result in further dilution to our existing stockholders and have antitakeover implications.”see in full comparison
“Our evaluation of strategic alternatives, including Mobix Labs’ proposal, may not result in a transaction or increased value for our stockholders and could create business disruption and stock price volatility.”see in full comparison
Full comparison: every changed paragraph (33)
Our
consolidated financial statements as of December 31, 20242025 have
been prepared under the assumption that we will continue as a going concern
for the next twelve months. As of December 31, 2024,2025, we had
cash and cash equivalents of $3.3$2.9 million and an accumulated deficit of $177.1
$181.9 million. We believe that our existing cash and cash equivalents
and expected receipts associated with forecasted product sales will enable us to meet our capital needs through at leastinto the second
third quarter of 2025.2026.
Our
ability to continue as a going concern is dependent upon our ability
to raise additional capital and to achieve sustainable revenues
and profitable operations. We will need to increase revenues substantially
beyond levels that we have attained in the past in order to
generate sustainable operating profit and sufficient cash flows to continue
doing business without raising additional capital from time
to time. As a result of our expected operating losses and cash burn for
the foreseeable future and recurring losses from operations,
if we are unable to raise sufficient capital through additional debt or equity
arrangements, there will be uncertainty regarding our
ability to maintain liquidity sufficient to operate our business effectively,effectively. whichAs
a raisesresult, management has concluded, and our independent registered public accounting firm has agreed with our conclusion that there is
substantial doubt as toregarding our ability to continue
as a going concern.concern for a period of at least 12 months beyond the filing of this Annual
Report on Form 10-K. If we cannot continue as a viable entity, our stockholders would likely lose most or all of their investment in us.
Taiwan
Semiconductor Manufacturing Corporation, or TSMC, is the sole foundry
that manufacturesmanufactured the wafers used to produce our memory IC products.
TSMCproducts, informed us that it would be discontinuingdiscontinued the foundry process used to produce thesuch wafers necessary to produce our memory ICs.wafers. As
we were not in a position to transition wafer production to a new foundry and continue to manufacture these products, we initiated an
end-of-life, or EOL, of our memory IC products in 2023, and ceased production of these products in 2024. As of December 31, 2024,2025, we had
hadno remaining EOL purchase orders from customers totaling approximately $2.3 million, and we expect to ship all of these orders by March
2025.customers. We do not expect any further shipments or to generate any meaningful revenue from shipments of our memory
IC products after
March December 2025. For the years ended December 31, 20242025 and 2023,2024, our memory IC products represented overapproximately 85% 22%
and 60%89% of our revenues, respectively.
The discontinuation of the production and sale of our memory IC products will negatively impact
our future revenues, results of operations
and cash flows.
In
addition, we maintain an inventory of our products at various stages
of production, as well as an inventory of finished goods. As we
are generally a sole-source supplier, we hold these inventories in anticipation
of customer orders. If those customer purchase orders
do not materialize in a timely manner or customers do not honor those purchase orders,
we can have excess or obsolete inventory which
we would have to write-down, and our gross profit and results of operations would be adversely
affected. During the years ended December
31, 20242025 and 2023,2024, we recorded inventory write-downs of approximately $0.4 million$36,000 and $3.5$0.4 million,
respectively.
We intend to continue spending to grow our business. If we do not achieve and maintain profitability, we will need additional financing to pursue our business strategy, develop new products, respond to competition and market opportunities and acquire complementary businesses or technologies. There can be no assurance that such additional capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such capital will be offered on terms and conditions acceptable to us. Adverse market conditions, volatility in the capital markets, declines in our stock price, changes in investor sentiment, interest rate increases, or factors specific to our business or industry could impair our ability to raise capital on terms favorable to us or at all. In addition, so long as our public float remains below $75 million, we are subject to the “baby shelf” limitations under General Instruction I.B.6 of Form S-3, which restricts the amount of securities we may sell under a shelf registration statement in any 12-month period to one-third of our public float. This limitation may constrain the amount of capital we can raise through our “at the market” offering program or through registered shelf offerings and may require us to rely on alternative, potentially more costly or time-consuming offering structures, such as registration statements on Form S-1.
Our
reduction in force undertaken to significantly reduce our ongoing operating expenses may not result in our intended outcomes and may
yield unintended consequences and additional costs.
In
November 2023, we implemented an employee lay-off and terminated certain consulting positions (the “Reductions”) to reduce
operating expenses and cash burn, as we prioritized business activities and projects that we believe will have a higher return on investment.
As part of the Reductions, we implemented a temporary lay-off that impacted 16 employees (the “Employees”) of Peraso Tech.
In 2024, we determined that we would not recall any of the 11 Employees that remained on our payroll and commenced notifying the remaining
Employees that their employment would be terminated. As a result, we recorded severance charges of approximately $0.4 million during
the year ended December 31, 2024, and, as of December 31, 2024, we had a remaining liability for severance costs of approximately $0.1
million. The accrued severance costs are expected to be paid through October 2025.
As
a result of the decision to not recall the Employees, we determined that it was probable that a number of our non-cancelable licenses
for computer-aided design software would not be utilized during the remaining license terms. During the three months ended June 30, 2024,
we expensed the value of the remaining contractual liabilities and recorded liabilities of approximately $1.6 million. As of December
31, 2024, we had a remaining liability of approximately $1.1 million, and we expect to pay these license fees through September 30, 2025.
In
addition to the costs associated with the non-cancelable license commitments for computer-aided design software, the Reductions may result
in other unintended consequences and costs, such as the loss of institutional knowledge and expertise, attrition beyond the intended
number of employees, decreased morale among our remaining employees, and the risk that we may not achieve the anticipated benefits of
the Reductions. In addition, while positions have been eliminated, certain functions necessary to our operations remain, and we may be
unsuccessful in distributing the duties and obligations of departed employees among our remaining employees. We may also be unsuccessful
in negotiating any desired strategic alternative or partnership relating to such functions on a timely basis, on acceptable terms, or
at all. The Reductions could also make it difficult for us to pursue, or prevent us from pursuing, new opportunities and initiatives
due to insufficient personnel, or require us to incur additional and unanticipated costs to hire new personnel to pursue such opportunities
or initiatives. Further, inflationary pressure may increase our costs, including employee compensation costs, or result in employee attrition
to the extent our compensation does not keep up with inflation, particularly if our competitors’ compensation does. If we are unable
to realize the anticipated benefits from the Reductions, if we experience significant adverse consequences from the reduction in force,
or if we are otherwise unable to retain our employees, our business, financial condition, and results of operations may be materially
adversely affected.
Failure
to comply with laws relating to employment could subject us to penalties and other adverse consequences.
We
are subject to various employment-related laws in the jurisdictions in which our employees are based. We face risks if we fail to comply
with applicable U.S. federal or state employment and wage laws, or employment wage laws applicable to our employees located in Canada.
The Reductions create an additional risk of claims being made on behalf of affected employees. Recently, the Company has received and,
may in the future receive, claims made on behalf of employees, whom were part of the Reductions, regarding statutory and common law severance
payments. If such claims are successful and not mitigated by employment practices insurance coverage, our required payments may be higher
than we have initially estimated. In addition, any violations of applicable wage laws or other labor- or employment-related laws could
result in complaints by current or former employees, adverse media coverage, investigations, and damages or penalties, which could have
a materially adverse effect on our reputation, business, operating results, and prospects. In addition, responding to any such proceeding
may result in a significant diversion of management’s attention and resources, significant defense costs, and other professional
fees.
As
discussed under “We discontinued the production of our
memory products,” TSMC, which is the sole foundry that manufactures
manufactured the wafers used to produce our memory IC products, informed us that it will be discontinuingdiscontinued the
foundry process used to produce the
waferssuch necessary to produce our memory ICs.wafers. We arewere not in a position to transition wafer production to a new foundry and continue to
manufacture these products. As a result, we initiated an EOL of our memory IC products. We do not expect to generate any meaningful revenue
from shipments of our memory IC products after December 2025. The discontinuation of the production and sale
of our memory IC products
will negatively impact our future revenues, results of operations and cash flows.
To date, we have not achieved the anticipated benefits of conducting business as a fabless semiconductor company.
Our
overall revenue has been highly concentrated,
with a few customers accounting for a significant percentage of our total revenue. For
the yearsyear ended December 31, 2025 our five largest
customers represented approximately 80% of our total revenue. For the year ended December 31, 2024 and 2023, our threetwo largest customers represented
approximately 86% and 75% of our total revenue,revenue. respectively.
We expect that a relatively small number of customers will continue to account for a substantial
portion of our revenue for the foreseeable
future.
We might also face credit risks associated with the
concentration of
our revenue among a small number of licensees and customers. At December 31, 2025, two customers represented approximately
93% of total trade receivables and at December 31, 2024, three customers represented approximately 91% of total
trade receivables and at December 31, 2023, three customers represented approximately 83% of total trade receivables. Our
failure to collect
receivables from any customer, which represents a large percentage of receivables, on a timely basis, or at all, could
adversely affect
our cash flow or results of operations.
We
have experienced and may continuein tothe future experience disruptions in
our global semiconductor supply chain, with suppliers increasing lead times or placing
products on allocation, including procuring necessary
components, wafers, substrates and assembly services in a timely fashion. AsIn the past, as a
result of these supply chain disruptions,
we have had to increase customer order lead times, and we may be required to purchase some
products on allocation. We may be unable to
satisfy all of the demand for our products, which may adversely affect customer relationships
and impact revenue.
Our evaluation of strategic alternatives, including Mobix Labs’ proposal, may not result in a transaction or increased value for our stockholders and could create business disruption and stock price volatility.
As described in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” we are evaluating a non-binding acquisition proposal from Mobix Labs as part of our ongoing exploration of strategic alternatives. There can be no assurance that any definitive agreement will be entered into, that any transaction will be consummated, or that the terms of any transaction, if completed, will be favorable to us or our stockholders. If we do not complete a transaction, the fact that we undertook a review of strategic alternatives that are not ultimately consummated could adversely affect our stock price and business. Conversely, if a transaction is completed, it may involve risks and uncertainties, including the potential for integration challenges, unforeseen liabilities, or other adverse effects on our business.
The process of reviewing potential strategic alternatives has been and may continue to be a significant distraction for our board of directors and management, and has required and may continue to require the expenditure of significant time and resources by us, which may cause concern to our employees, investors, strategic partners, and other constituencies and may have a material impact on our business and operating results and/or result in increased volatility in our share price.
The occurrence of any one or more of the above risks could have a material adverse impact on our business, financial condition, results of operations and cash flows.
Current or future tariffs or other restrictive trade measures may raise the costs of raw materials, components or finished goods, which may adversely impact both our product offerings and our operational expenses. Such cost increases may reduce our margins and require us to increase prices, which could harm our competitive position, reduce customer demand and damage customer relationships.
Trade disputes, trade restrictions, tariffs and other political tensions between the U.S. and other countries may also exacerbate unfavorable macroeconomic conditions including inflationary pressures, foreign exchange volatility, financial market instability, and economic recessions or downturns, which may also negatively impact customer demand for our products or services, delay purchases or renewals, limit expansion opportunities with customers, limit our access to capital, or otherwise negatively impact our business and operations. Ongoing tariff, trade restrictions and macroeconomic uncertainty has and may continue to contribute to volatility in the price of our common stock.
Ongoing uncertainty regarding trade policies may also complicate our short- and long-term strategic planning, and that of our partners and customers, including decisions regarding hiring, product strategy, capital investment, supply chain design and geographic expansion.
While we continue to monitor trade developments, the ultimate impact of these risks remains uncertain and any prolonged economic downturn, escalation in trade tensions, or deterioration in international perception of U.S.-based companies could materially and adversely affect our supply chain, as well as our business, results of operations and financial condition. In addition, tariffs and other trade developments have and may continue to heighten the risks related to the other risk factors described in this Report.
On
March 3, 2025, the President of the United States announced the imposition of new tariffs on imports from Mexico and Canada, to take
effect on March 4, 2025. Effective at 12.01 a.m. ET on March 4, 2025, all goods arriving at U.S. ports and originating from Canada or
Mexico are subject to 25 percent tariffs, with some exceptions. Effective February 4, 2025, all goods presented for entry at U.S. ports
and originating from China, including Hong Kong, are subject to a 10 percent tariff on Chinese imports. The impact of these potential
tariffs on our business and financial condition, if any, is subject to a number of factors that are not yet known, including any countermeasures
that the target countries may take in response to such tariffs. In light of these uncertainties, we can provide no assurance that any
mitigating actions that may become available to us, such as our ability to pass along some or all of the costs of any tariffs to some
or all of our customers, will be successful.
In
addition to potential increases in customs duties and tariffs in the United States and other countries, the United States-Mexico-Canada
Agreement, or USMCA, is subject to renewal in 2026. There can be no assurance that any newly negotiated terms in the USMCA will not adversely
affect our business and the business of our customers. It remains unclear what specific actions the current U.S. administration may take
to resolve trade-related issues with China and other countries.
As
of December 31, 2024,2025, we had approximately $212.1$214 million of net operating
loss, or NOL, carryforwards for U.S. federal tax purposes.
Under U.S. federal income tax law, we generally can use our NOL carryforwards
(and certain related tax credits) to offset ordinary taxable
income, thereby reducing our U.S. federal income tax liability, for up to
20 years from the year in which the losses were generated,
generated for the years before 2018, after which time they will expire. Our California
NOL carryforwards (and certain related tax credits) generally may be used to offset
future state taxable income for 20 years from the
year in which the losses are generated, depending on the state, after which time they
will expire. The rate at which we can utilize our
NOL carryforwards is limited (which could result in NOL carryforwards expiring prior
to their use) each time we experience an “ownership
change,” as determined under Section 382 of the Internal Revenue Code.
A Section 382 ownership change generally occurs if a shareholder
or a group of shareholders who are deemed to own at least 5% of our
common stock increase their ownership by more than 50 percentage points
over their lowest ownership percentage within a rolling three-year
period. If an ownership change occurs, Section 382 generally would
impose an annual limit on the amount of post-ownership change taxable
income that may be offset with pre-ownership change NOL carryforwards
equal to the product of the total value of our outstanding equity
immediately prior to the ownership change (reduced by certain items
specified in Section 382) and the U.S. federal long-term tax-exempt
interest rate in effect at the time of the ownership change. A number
of special and complex rules apply in calculating this Section
382 limitation. While the complexity of Section 382 makes it difficult
to determine whether and when an ownership change has occurred,
and a formal study has not been performed, we believe that a Section 382
ownership change occurred as a result of our business combination
with Peraso Technologies Inc. in 2021. We believe this Section 382 limitation
will result in substantially all of our federal and state
NOLs and federal tax credit carryforwards incurred prior to December 2021 expiring
before they can be utilized. In addition, our ability
to use our NOL carryforwards will be limited to the extent we fail to generate enough
taxable income in the future before they expire.
Existing and future Section 382 limitations and our inability to generate enough taxable
income in the future could result in a substantial
portion of our NOL carryforwards expiring before they are used. We have recorded a
full valuation allowance for our deferred tax assets.
Geopolitical
issues around the world can impact
macroeconomic conditions and could have a material adverse impact on our business. For instance,
world unrest due to wars, terrorist attacks
and other disruptive events, such as the COVID-19 pandemic, have led to global economic disruptions,
and mounting inflationary cost pressures
and recessionary fears have negatively impacted the global and domestic economy. Since mid-2022,
the U.S. Federal Reserve has addressed elevated inflation by periodically increasing interest rates. Given current market conditions,
we may be unable to
access the capital markets, and additional capital may only be available to us on terms that could be significantly
detrimental to our
existing stockholders and to our business.
Inflation
rates in the markets in which we operate
have increased and may continue to rise. Inflation overin the last tworecent years has led us to experience
higher costs, including, among others, labor,
wafer and transportation. Our suppliers have raised their prices and may continue to raise
prices, and, although we have made minimal
price increases thus far, in the competitive markets in which we operate, we may not be able
to make corresponding price increases to
preserve our gross margins and profitability. In addition, inflationary pressures could cause
customers to delay or reduce purchases of
our products or delay payments to us. If inflation rates continue to rise or remain elevated
for a sustained period of time, they could
have a material adverse effect on our business, financial condition, results of operations
and liquidity.
The
sale of our common stock resulting from the exercise of any options or vesting of restricted stock units granted to executive officers
and other employees under our equity compensation plan and the exercise of any warrants, and other issuances of our common stock could
have an adverse effect on the market price of the shares of our common stock. We are generally not restricted from issuing additional
shares of common
stock, including any securities that are convertible into or exchangeable for, or that represent the right to receive
shares of common
stock, provided that we are subject to the listing rules of the Nasdaq Stock Market (which generally require stockholder
approval for
any transactions which would result in the issuance of more than 20% of our then outstanding shares of common stock or voting
rights representing
over 20% of our then outstanding shares of stock). Sales of a substantial number of shares of our common stock in
the public market or
the perception that such sales might occur could materially adversely affect the market price of the shares of our
common stock. Because
our decision to issue securities in any future offering will depend on market conditions and other factors beyond
our control, we cannot
predict or estimate the amount, timing or nature of our future offerings. Accordingly, our stockholders bear the
risk that our future
offerings will reduce the market price of our common stock and dilute their stock holdings in us. In addition, issuances of our common
stock resulting from the exercise of options or vesting of restricted stock units granted under our equity compensation plan and the exercise
of any warrants, and other issuances of our common stock could have an adverse effect on the market price of the shares of our common
stock.
The
effective increase in the number of shares of our common stock available for issuance as a result of our reverse stock split could result
in further dilution to our existing stockholders and have antitakeover implications.
The
reverse stock split effected in January 2024 alone had no effect on our authorized capital stock, and the total number of authorized
shares remains the same as before the reverse stock split. The reverse stock split of our issued and outstanding shares increased the
number of shares of our common stock (or securities convertible or exchangeable for our common stock) available for issuance by decreasing
the number of shares of our common stock issued and outstanding. The additional available shares are available for issuance from time
to time at the discretion of our board of directors when opportunities arise, without further stockholder action or the related delays
and expenses, except as may be required for a particular transaction by law, the rules of any exchange on which our securities may then
be listed, or other agreements or restrictions. Any issuance of additional shares of our common stock would increase the number of outstanding
shares of our common stock and (unless such issuance was pro-rata among existing stockholders) the percentage ownership of existing stockholders
would be diluted accordingly. In addition, any such issuance of additional shares of our common stock could have the effect of diluting
the earnings per share and book value per share of outstanding shares of our common stock.
Additionally,
the effective increase in the number of shares available for issuance could, under certain circumstances, have anti-takeover implications.
For example, the additional shares of common stock that have become available for issuance could be used by us to oppose a hostile takeover
attempt or to delay or prevent changes in control or our management. Although our reverse stock split is prompted by other considerations
and not by the threat of any hostile takeover attempt, stockholders should be aware that our reverse stock split could facilitate future
efforts by us to deter or prevent changes in control, including transactions in which our stockholders might otherwise receive a premium
for their shares over then-current market prices.
Management's Discussion & Analysis (MD&A)
New heading “Unsolicited, Non-binding Proposal from Mobix Labs, Inc.; Strategic Review Process”
Removed heading “Warrant Inducement Offering”
Removed heading “Gain on license and asset sale”
Largest changes
“In 2023, we used $4.7 million in cash from operating activities, which primarily resulted from our net loss of $16.8 million and changes to operating assets and liabilities of approximately $2.8 million, adjusted for non-cash charges and gains, including stock-based compensation expenses of $5.2 million, depreciation and amortization expenses of $3.8 million, $3.6 million in inventory write-downs and $0.3 million of asset impairment charges, partially offset by a $3.5 million non-cash gain on the change in fair value of warrant liability and $0.1 million of other changes. …”see in full comparison
We incurred net losses of approximatelysee in full comparison$10.7$4.8 million and$16.8$10.7 million for the years ended December 31,20242025 and2023,2024, respectively, and we had an accumulated deficit of approximately$177.1$181.9 million as of December 31,2024.2025. These and prior year losses have resulted in significant negative cash flows and have required us to raise substantial amounts of additional capital. As a result, management has concluded, and our independent registered public accounting firm has agreed with our conclusion, that there is substantial doubt regarding our ability to continue as a going concern for a period of at least 12 months beyond the filing of this Annual Report on Form 10-K. To date, we have primarily financed our operations through loans, offerings of common stock and warrants and issuances of convertible notes.
“Unsolicited, Non-binding Proposal from Mobix Labs, Inc.; Strategic Review Process”see in full comparison
Cost of net revenue decreased forsee in full comparison20242025 compared with2023,2024, primarilyduerelated to the decrease in productmix,revenue and amortization of developed technology intangible assets of approximately $2.3 million incurred in 2024, assalesthese assets were fully amortized as ofourDecembermemory IC products increased, and a reduction in inventory write-down charges. Our memory products generate higher margins than our mmWave products, for which we experienced reduced sales during31, 2024. Inventory write-down charges declined bybyapproximately$3.1 million$374,000 from$3.5 million recorded in 2023 to$0.4 million recorded in2024.2024 to approximately $36,000 recorded in 2025. The previous write-downs were primarily attributable to inventory identified as excess and obsolete based on inventory expiration and customer forecasts.If our utilization of inventory is, or if our estimates of our inventory’s potential utility become, less favorable than currently expected, additional inventory write-downs may be required.
Full comparison: every changed paragraph (51)
Our
strategy and primary business objective is to be a profitable,
IP-rich fabless semiconductor company offering integrated circuits, or
ICs, antenna modules and related non-recurring engineering services.
We specialize in the development of mmWave semiconductors, primarily
in the unlicensed 60 GHz spectrum band for 802.11ad/ay-compliant
devices and in the 28/39 GHz spectrum bands for 5G-compliant devices.
We derive our revenue from selling semiconductor devices, as well
as antenna modules based on using those mmWave semiconductor devices.
We have pioneered a high-volume mmWave IC production test methodology
using standard, low-cost production test equipment. It has taken
us several years to refine performance of this production test methodology,
and we believe this places us in a leadership position in
addressing the operational challenges of delivering mmWave products into high-volume
markets. We also produce and sell complete mmWave
antenna modules. The primary advantage provided by our antenna modules is that our proprietary
mmWave ICs and the antenna are integrated
into a single device. A differentiating characteristic of mmWave technology is that the RF amplifiers
must be as close as possible to
the antenna to minimize loss. WithOur ourmodule module,is wedesigned canto guaranteeenhance the performance of the amplifier/antenna
interface and simplify customers’
radio frequency (“RF”) engineering, facilitating more opportunities for customer prospects
that have not provided RF-type
systems, as well as shortening the time to market for new products.
We
also had a memory product line comprising our Bandwidth
Engine IC products. These products integrate our proprietary, 1T-SRAM high-density
embedded memory and a highly-efficient serial interface protocol resulting in a monolithic memory IC solution optimized for memory bandwidth
and transaction access performance. Taiwan Semiconductor Manufacturing Corporation, or TSMC, is the sole foundry that manufacturesmanufactured the
wafers used to produce
our memory IC products.products, TSMC informed us that it would be discontinuingdiscontinued the foundry process used to produce wafers,
insuch turn, necessary to manufacture our memory ICs.wafers. As a result, in May 2023, we initiated an end-of-life,
or EOL, of our memory IC products,
and and, in March 2025, we commencedfulfilled initialall then-outstanding EOL shipments during the quarter ended September 30, 2023. As of December 31, 2024, we had remaining EOL purchase
orders totaling approximately $2.3 million, and we expect to ship all of these orders by March 2025. We do not expect any further
shipments or to generate any revenue from shipments offor our memory IC productsproducts. afterSubsequent
to March 2025, we received additional purchase orders and recorded revenue totaling approximately $0.5 million during the second half
of 2025.
Unsolicited, Non-binding Proposal from Mobix Labs, Inc.; Strategic Review Process
On June 27, 2025, we confirmed in a public press release the receipt of an unsolicited, non-binding proposal from Mobix Labs, Inc. (“Mobix Labs”) to acquire all of the Company’s issued and outstanding equity securities in exchange for newly issued shares of Mobix Labs common stock, with a fixed exchange ratio based on the average daily closing price of our common stock over the 30 calendar days ending on June 11, 2025, plus a 20% premium, or approximately $1.20 per share.
On July 11, 2025, we issued a press release announcing the initiation of the strategic review process. Following this, our financial advisor contacted potential counterparties to invite them to participate in the process subject to such parties’ execution of our standard non-disclosure agreement, which includes a standstill provision. Our financial advisor also contacted Mobix Labs to request that Mobix Labs execute our non-disclosure agreement in order to participate in the process, which Mobix Labs declined to execute.
On August 19, 2025, we issued a public press release providing an update on our strategic review process, including our engagement with potential counterparties and our continued openness to engaging with Mobix Labs and others, while noting that Mobix Labs declined to enter into our standard non-disclosure agreement and indicated it would not agree to receive material non-public information (“MNPI”).
On September 8, 2025, we issued a press release providing another update on our strategic review process, including regarding the two letters that we received from Mobix Labs, dated as of September 4, 2025, and September 5, 2025, in connection with its unsolicited offer to acquire all outstanding shares of the Company. The September 4 letter included a revised acquisition proposal involving a combination of cash and stock consideration in an undetermined amount, and a reiteration of Mobix Labs’ refusal to enter into a confidentiality agreement or receive MNPI from us. The September 5 follow-up letter stated that while Mobix Labs continued to oppose any standstill restrictions, it would be willing to consider a limited confidentiality arrangement to permit us to share MNPI deemed reasonably necessary, provided that such arrangement did not include a standstill and did not indefinitely constrain Mobix Labs. In response to such letters, we authorized a limited exploratory call with Mobix Labs, and we requested that any such discussion take place without us sharing any MNPI and outside the bounds of a confidentiality agreement, which exploratory call would serve to allow us to better understand Mobix Labs’ revised proposal and intentions.
On September 11, 2025, following the limited exploratory call with Mobix Labs on September 10, 2025, Mobix Labs issued a public statement describing the discussions had in such limited exploratory call and announcing an enhanced proposal of approximately 30% cash and 70% Mobix Labs common stock. Then, on September 12, 2025, we issued a press release to provide clarification to all stockholders relating to such public statements made by Mobix Labs, including that we did not respond to Mobix Labs’ proposal and that we did not agree to continue discussions with Mobix Labs during the call, and we sent a letter to Mobix Labs to clarify our position.
On September 13, 2025, Mobix Labs filed a Form 425 with the SEC and issued a related press release announcing its intent to commence a hostile exchange offer to acquire all outstanding shares of the Company. In the press release, Mobix Labs stated that the proposed offer is expected to consist of a mix of cash and Mobix Labs common stock, with an intended closing timeline of approximately 75 days.
On September 29, 2025, Mobix Labs delivered another letter to our board of directors reiterating its interest in a business combination and submitting what it described as a definitive proposal to acquire all outstanding shares of the Company for $1.30 per share, consisting of a mix of cash and Mobix Labs common stock, and also separately requested our cooperation with respect to an anticipated registration statement on Form S-4.
On October 3, 2025, Mobix Labs delivered an updated letter superseding its prior proposal and proposing to acquire all outstanding shares of the Company for $1.30 per share in cash, stating that the proposal was not subject to financing contingencies and was based on our publicly reported share count as of June 30, 2025.
On October 6, 2025, we sent a letter to Mobix Labs acknowledging receipt of its revised proposal and requesting clarification regarding share count assumptions, treatment of the Company’s publicly disclosed warrants and equity-linked instruments, and financing sources. Also on October 6, 2025, Mobix Labs issued a press release publicly announcing its updated all-cash proposal and reiterating its preference for a cooperative process with the Company.
On October 30, 2025, we entered into a mutual confidentiality agreement with Mobix Labs in connection with our ongoing review of strategic alternatives. The confidentiality agreement contains customary terms, including mutual 12-month standstill and non-solicitation provisions. On November 3, 2025, Mobix Labs issued a press release publicly announcing its entry into a mutual confidentiality agreement with us.
On January 21, 2026, Mobix Labs issued a press release, and we filed a Current Report on Form 8-K disclosing that the Company and Mobix Labs continue to engage in discussions regarding a potential strategic transaction and are conducting customary, confidential diligence and that Mobix Labs delivered to the Company a non-binding indication of interest contemplating a potential all-stock transaction at a premium to the Company’s trading price, subject to further diligence, negotiation, and the execution of definitive documentation.
Our board of directors is evaluating the Company’s options to enhance stockholder value. Our board of directors and management team are committed to acting in the best interests of all stockholders. Consistent with its fiduciary duties and in consultation with the Company’s financial and legal advisors, our board of directors will continue to carefully review Mobix Labs’ proposal to determine the course of action that it believes is in the best interest of the Company and its stockholders. We do not intend to make further comments regarding potential transactions or provide any public updates regarding proposed or potential transactions, unless required by applicable law or a regulatory body. There can be no assurance that any transaction will be completed with Mobix Labs or any other third party.
On
August 30, 2024, we entered into an At The
Market Offering Agreement (the “Sales Agreement”) with Ladenburg Thalmann &
Co. Inc. (“Ladenburg”) with respect
to an “at the market” offering program, under which we may, from time to
time, in our sole discretion, issue and sell through
Ladenburg, acting as agent or principal, shares of our common stockstock. initiallyOn having
anNovember aggregate21, offering2025, pricewe offiled upa prospectus supplement to $1,425,000.our Afterregistration
statement sellingon $169,215Form ofS-3 shares(File pursuantNo. 333-280798) to the Sales Agreement, on December 10, 2024,
we increasedincrease the maximum aggregatenumber offeringof amountshares of common stock issuableto pursuantup to thean Salesaggregate Agreementof to$3,150,000
of $2,693,527.shares, exclusive of previously sold shares. The Sales
Agreement provides that Ladenburg will be entitled to compensation for its services
equal to 3.0% of the gross proceeds from sales
of any shares of common stock pursuant to the Sales Agreement in addition to the reimbursement
of certain expenses. We have no obligation
to sell any shares pursuant to the Sales Agreement and either we or Ladenburg may terminate
the Sales Agreement in accordance with its
terms. During the three and twelve months ended December 31, 2024,2025, we sold 153,2001,710,732 and 3,713,939
shares of common stock for net proceeds of approximately
$186,500 $2,095,000 and $4,351,100 pursuant to the Sales Agreement.Agreement
The
shares of common stock we may issue or sell pursuant to the Sales Agreement are registered under our Registration Statement on Form S-3
(File No. 333-280798), which was declared effective by the SEC on July 22, 2024. We are currently subject to the limitations contained
in General Instruction I.B.6 of Form S-3. As a result, we are limited to selling no more than one-third of the aggregate market value
of the equity held by non-affiliates, or the public float, during any 12-month period. If our public float increases, we will have additional
availability under such limitations, and if our public float increases to $75 million or more, we will no longer be subject to such limitations.
There can be no assurance that our public float will increase or that we will no longer be subject to such limitations.
Warrant
Inducement Offering
On August 6, 2024, we extended
the expiration date of our outstanding Series B warrants, which were issued in a public offering completed in February 2024, to October
7, 2024, by entering into an amendment to the Warrant Agency Agreement dated as of February 8, 2024 by and between us and the warrant
agent, Equiniti Trust Company, LLC (the Warrant Agency Agreement). On October 3, 2024, we extended the expiration date of the Series B
warrants to November 8, 2024, by entering into a second amendment to the Warrant Agency Agreement. The Series B warrants would otherwise
have expired on October 7, 2024. See Note 10 of the consolidated financial statements for additional information about the Series B warrants
and the offering. On November 5, 2024, we entered into inducement offer letter agreements (the “Inducement Letters”)
with certain holders (the “Holders”) of existing Series B warrants (the “Existing Warrants”) to purchase up to
an aggregate of 2,246,030 shares of the Company’s common stock, having an original exercise price of $2.25 per share, issued to
the Holders on February 8, 2024 in the offering (see Note 10 of the consolidated financial statements). Pursuant to the Inducement Letters,
the Holders agreed to exercise for cash their Existing Warrants at a reduced exercise price of $1.30 per share (the “Reduced Exercised
Price”) for gross proceeds of approximately $2.92 million in consideration for the Company’s agreement to issue in a private
placement (i) new Series C common stock purchase warrants (the “Series C Warrants”) to purchase an aggregate of 2,246,030
shares of common stock, and (ii) new Series D common stock purchase warrants (the “Series D Warrants,” and collectively with
the Series C Warrants, the “New Warrants”) to purchase an aggregate of 2,246,030 shares of common stock. Each New Warrant
has an exercise price equal to $1.61 per share, subject to adjustment as provided in the New Warrants. The Series C Warrants were exercisable
upon issuance and expire on the six-month anniversary of the date of issuance. The Series D Warrants were exercisable upon issuance and
expire on the five-year anniversary of the date of issuance. During the quarter ended December 31, 2024, we received net proceeds of approximately
$2.6 million from the warrant inducement offering.
Our
Historically, our licensing contracts for our memory technology typically provide
provided for royalties based on the licensee’s use of our memory technology in its currently shipping
commercial products. We estimate its estimated
royalty revenue in the calendar quarter in which the licensee uses the licensed technology. Payments
are were received in the subsequent quarter.
Royalty revenues from licensees of our memory technology are no longer material due to reduced shipments by these licensees, which we
attribute to the discontinuation of the foundry process by TSMC, therefore royalty revenue is recorded when a licensee reports actual
amounts to us. We also generate revenue from licensing itsour mmWave technology. We recognize Licenselicense feefees as revenue at
the point of time
when the control of the license has been transferred and we have no continuing performance obligations to the customer.
We periodically issue stock options and restricted stock units (RSUs) to employees and non-employees. We account for such awards based on ASC 718, whereby the value of the award is measured on the date of award and recognized as compensation expense on a straight-line basis over the vesting period. The fair value of our stock options is estimated using the Black-Scholes-Merton Option Pricing (Black-Scholes) model, which uses certain assumptions related to risk-free interest rates, expected volatility, expected life of the options, and future dividends. Compensation expense is recorded based upon the value derived from the Black-Scholes model. The assumptions used in the Black-Scholes model could materially affect compensation expense recorded in future periods. The fair value of restricted stock awards, restricted stock units, and performance-based restricted stock units is based on the closing price of our common stock on the date of grant. Recognition of compensation expense for non-employees is in the same period and manner as if we had paid cash for the services.
We
recognize stock-based compensation for equity awards on a straight-line basis over the requisite service period, usually the vesting
period, based on the grant-date fair value. We estimate the value of employee stock options on the date of grant using the Black-Scholes
option pricing model. The determination of fair value of share-based payment awards on the date of grant using an option pricing model
is affected by our stock price, as well as assumptions regarding a number of highly complex and subjective variables. These variables
include, but are not limited to, the expected stock price volatility over the term of the awards, and actual and projected employee stock
option exercise behaviors. The expected term of options granted is derived from historical data on employee exercises and post-vesting
employment termination behavior. The expected volatility is based on the historical volatility of our stock price. The fair value of
restricted stock awards, restricted stock units, and performance-based restricted stock units is based on the closing price of the Company’s
common stock on the date of grant.
Product
revenue increaseddecreased for 20242025 compared with 2023 2024
primarily due to the decrease of our memory IC product shipments attributable to the significant reduction in EOL shipments in 2025 as
compared with 2024. The decreases were partially offset by an increase in shipments of our memory IC products due to the EOL we
initiated in 2023. The increase in memory shipments was partially offset by a decrease in shipments of our mmWave products.ICs and antenna modules.
We
expect sales of our mmWave products to increase
from a volume and revenue perspective overin the next 12 months,2026, as we expect i) an increase
in orders from existing customers,customers which appear to have reduced inventory levels that had increased due to the worldwide inventory correction
and ii) new customers to
commence production during 2025.2026.
Royalty
and other revenue includes royalty, non-recurring
engineering services and license revenues. The decreaseincrease in royalty and other revenue
for 20242025 compared with 20232024 was primarily due to
an a decreaseincrease in non-recurring engineering services revenue related to our mmWave technology combinedattributable to a statement of work entered
withinto in July 2025 partially offset by a decrease in royalties from licensees of our memory technology,technology due to reduced shipments by these
licensees, which werewe impactedattribute to the discontinuation of the foundry process by the same factors that produced our EOL.TSMC.
Cost
of net revenue is primarily comprised of direct
and indirect costs related to the sale of our products, including amortization of certain
intangible assets and depreciation of production-related fixed assets and, prior to January
1, 2025, amortization of intangible assets.
Cost of net revenue decreased for 20242025 compared with 2023,
2024, primarily
due related to the decrease in product mix,revenue and amortization of developed technology intangible assets of approximately
$2.3 million incurred in 2024, as salesthese assets were fully amortized as of ourDecember memory IC products increased, and a reduction in inventory write-down charges. Our memory products
generate higher margins than our mmWave products, for which we experienced reduced sales during31, 2024. Inventory write-down charges declined by
byapproximately $3.1 million$374,000 from $3.5 million recorded in 2023 to $0.4 million recorded in 2024.2024 to approximately $36,000 recorded in 2025. The previous write-downs were primarily
attributable to inventory
identified as excess and obsolete based on inventory expiration and customer forecasts. If our utilization of inventory is, or if our
estimates of our inventory’s potential utility become, less favorable than currently expected, additional inventory write-downs
may be required.
Gross profit increaseddecreased for 20242025 compared with 20232024 primarily due to
the reduction in revenue combined with product mix, specifically the increasedecrease in memory IC shipments andpartially reductionoffset by an increase in
mmWave product shipmentsshipments. The gross margin percentage increased in 2025 compared with 2024 due to approximately $2.3 million of amortization
of intangible assets recorded to cost of net revenue combined with a $3.1 million$374,000 decrease
in inventory write-down charges in 20242025 compared
with 2023.2024. DuringIn addition, during the year ended December 31, 2024,2025, we recorded revenue for sales of approximately
$139,000 frommmWave inventory with a cost of
approximately $1,351,000 that had been written down in prior periods.to January 1, 2025.
Research
and Development (R&D)
Our
research and development, or R&DD, expenses
include costs related to the development of our products. We expense R&D costs as they are incurred.
The decrease for 2025 compared with 2024 was primarily due to: i) reduced salary and consulting costs, as we implemented reductions in force during 2024 and terminated consultant contracts, ii) reduced rent expense, as our San Jose office lease expired in January 2025, and iii) reduced software license expense, as, during 2024, we accrued the value of certain of our software license obligations and certain other licenses expired in the second half of 2025.
The
decrease for 2024 compared with 2023 was primarily due to reduced salary and consulting costs. During
2023 and 2024 we implemented workforce reductions, as well as targeted reductions in certain longer-term research and development
projects.
We
expect that total R&D expenses will increase during 2025 compared with 2024, as a result of continued development of our mmWave products
and headcount additions to support anticipated increased customer activity.
Selling,
General and Administrative (SG&A)
Selling,
general and administrative, or SG&A,
expenses consist primarily of personnel and related overhead costs for sales, marketing, finance,
human resources and general management
and, andprior to January 1, 2025, amortization of certain intangible assets.
The
increase decrease for 20242025 compared with 20232024 was primarily
attributable to increasedreductions consultingin expenses for facilities, stock based compensation and professional services costs and increased
amortization of purchased intangible assets for customer
relationships relationships,of approximately $1.0 million, which were fully amortized as we reduced the estimated life of theseDecember intangibles31, during
2023.2024. These increasesdecreases were partially offset
by the impact of headcount reductions initiatedincreases in 2023, including the elimination of certain
employeeconsulting and consultingprofessional positionsservices and reductions of other discretionary operating expenses during 2023.costs.
We
expect that total SG&A expense will remain flat or slightly increase during 2025 compared with 2024 as we continue to secure new
customers for and continue to invest in the development of our products.
In November 2023, we implemented
an employee lay-off
and terminated certain consulting positions (the “Reductions”) to reduce operating expenses and cash burn,
as we prioritized
business activities and projects that we believe will have a higher return on investment. As part of the Reductions,
we implemented a
temporary lay-off that impacted 16 employees (the “Employees”) of Peraso Tech. During the six months ended
June 30, 2024,
we determined that we would not recall any of the 11 Employees that remained on our payroll and commenced notifying the
remaining Employees
that their employment would be terminated. As a result, we recorded severance charges of approximately $0.4 million
for the year ended
December 31, 2024. The severance liabilities were fully paid as of December 31, 2024.2025.
As a result of the decision to not recall the Employees,
we determined
that it was probable that a number of our non-cancelable licenses for computer-aided design software would not be utilized
during the
remaining license terms. During the year ended December 31, 2024, we expensed $1.6 million for the value of the remaining contractual liabilities
liabilities.and recorded liabilities of approximately $1.6 million. During the three months ended June 30, 2025, a licensor terminated one of the
license agreements and initiated a refund of approximately $56,300 for amounts previously paid by us. As a result, we reversed approximately
$222,600 of expense and approximately $166,300 of the related contractual liabilities for this licensor during the three months ended
June 30, 2025. As of December 31, 2025, the remaining contractual liabilities had been paid.
Gain on
license and asset sale
On
August 5, 2022, we entered into a Technology License and Patent Assignment Agreement (the Intel Agreement) with Intel Corporation (Intel).
As consideration, Intel paid us $3,062,500 in August 2022 and $437,500 (the Holdback) in January 2023 upon the satisfaction by us of
certain release criteria set forth in the Intel Agreement regarding the Licensed Technology. We determined that the license and
asset sale did not qualify as a sale of a business, but as a sale of a non-financial asset, with the resultant gain recorded as income
from operations. In January 2023, upon receipt of the Holdback, we recognized a gain, net of transaction costs, which was recorded
as a reduction of operating expenses in the consolidated statements of operations.
In 2025, we used $5.6 million in cash from operating activities, which primarily resulted from our net loss of $4.8 million, adjusted for non-cash charges and gains, including stock-based compensation expenses of $0.5 million, depreciation and amortization expenses of $0.3 million, shares issued for services of $0.1 million and approximately $36,000 in inventory write-downs, partially offset by $1.7 million of changes to operating assets and liabilities.
In 2025, net cash used in investing activities was approximately $107,000 which was attributable to the purchase of fixed assets.
In
2023, we used $4.7 million in cash from operating activities, which primarily resulted from our net loss of $16.8 million and changes
to operating assets and liabilities of approximately $2.8 million, adjusted for non-cash charges and gains, including stock-based compensation
expenses of $5.2 million, depreciation and amortization expenses of $3.8 million, $3.6 million in inventory write-downs and $0.3 million
of asset impairment charges, partially offset by a $3.5 million non-cash gain on the change in fair value of warrant liability and $0.1
million of other changes. The changes in assets and liabilities primarily related to the timing of the collection of receivables from
customers, payments to vendors and increases in inventory balances.
In
2023, 2025, net cash provided fromby investingfinancing activities of $1.0$5.3 million
primarily comprised $0.9 million representedin $1.1net proceeds from a warrant inducement offering in September 2025 and $4.4 million of net proceeds
from maturities and sales ofunder short-term
investments,our partiallyat-the offsetmarket byoffering $0.1 million of purchases of fixed assets.program.
In
2023, net cash provided by financing activities was $3.4 million and consisted of $3.6 million in net proceeds from a registered direct
offering of our common stock and common stock purchase warrants completed in June 2023, partially offset by taxes paid to net share settle
equity awards and repayment of finance lease liabilities.
Our
primary purchase obligations include non-cancelable
purchase orders for inventory. At December 31, 2024,2025, the Companywe had outstanding
non-cancelable purchase orders for inventory, primarily wafers
and substrates, and related expenditures of approximately $3.1$2.7 million.
We
incurred net losses of approximately $10.7$4.8 million and $16.8$10.7 million
for the years ended December 31, 20242025 and 2023,2024, respectively, and
we had an accumulated deficit of approximately $177.1$181.9 million as of
December 31, 2024.2025. These and prior year losses have resulted in significant
negative cash flows and have required us to raise substantial
amounts of additional capital. As a result, management has concluded, and our independent registered public accounting firm has agreed
with our conclusion, that there is substantial doubt regarding our ability to continue as a going concern for a period of at least 12
months beyond the filing of this Annual Report on Form 10-K. To date, we have primarily financed our
operations through loans, offerings
of common stock and warrants and issuances of convertible notes.
We
expect to continue to incur operating losses during 2025,
2026, as we willdo ceasenot expect to generate any meaningful revenue from shipments of our remaining memory products after March 2025 and as we continue
to secure
new customers for and continue to invest in the development of our mmWave products. Further, we expect our cash expenditures to continue
to exceed receipts for at least the next 12 months, as our revenues will not be sufficient to offset our operating expenses. In addition,
we have incurred and may continue to incur substantial costs related to our strategic alternative exploration process, including our evaluation
of Mobix Labs’ proposal, which costs include the fees of our financial and legal advisors. We believe
that our existing cash and
cash equivalents as of December 31, 20242025 and expected receipts associated with forecasted product sales will enable us to meet our capital
needs through at leastinto the second
third quarter of 2025.2026.
We
will need to increase revenues beyond the levels that we have attained
in the past in order to generate sustainable operating profit
and sufficient cash flows to continue doing business without raising additional
capital from time to time. As a result of our expected
operating losses and cash burn and recurring losses from operations, if we are
unable to raise sufficient capital through additional
debt or equity arrangements, there will be uncertainty regarding our ability to
maintain liquidity sufficient to operate our business
effectively, which raises substantial doubt as to our ability to continue as a going
concern within one year from the date of issuance
of theseour consolidated financial statements. The consolidated financial statements presented
in Item 8 of this Report have been prepared
assuming that we will continue as a going concern, and do not include any adjustments that
might result from the outcome of this uncertainty.
There can be no assurance that such additional capital, whether in the form of debt
or equity financing, will be sufficient or available
and, if available, that such capital will be offered on terms and conditions acceptable
to us. We are currently seeking additional financing
in order to meet our cash requirements for the foreseeable future. If we are unsuccessful
in these efforts, we will need to implement
additional cost reduction strategies, which could further affect itsour near- and long-term business
plan. These efforts may include, but
are not limited to, reducing headcount and curtailing business activities. As further discussed in Note 10 to the consolidated financial
statements, in November 2024, we entered into a warrant inducement offering for net proceeds of approximately $2.6 million. Additionally,
on August 30, 2024, we entered into the Sales Agreement with Ladenburg, pursuant to which we may offer and sell, from time to time at
our sole discretion, shares of our common stock through Ladenburg as agent and/or principal (subject to the limitations of General Instruction
I.B.6 of Form S-3) through an at-the-market program. Further, during 2023 and 2024, we implemented reductions in our workforce and eliminated
19 full-time equivalent positions. These cost reduction actions were intended to preserve cash, as we kept capital expenditures to minimum
levels in order to reduce operating costs and our short-term cash needs.
As further discussed in Note 10 to the consolidated financial statements, we completed warrant inducement offerings in September 2025 and November 2024 for net proceeds of approximately $0.9 million and $2.6 million, respectively. Additionally, on August 30, 2024, we entered into the Sales Agreement with Ladenburg, pursuant to which we may offer and sell, from time to time at our sole discretion, shares of our common stock through Ladenburg as agent and/or principal (subject to the limitations of General Instruction I.B.6 of Form S-3) through an at-the-market program. During the three and twelve months ended December 31, 2025, we sold 1,710,732 and 3,713,939 shares of common stock for proceeds of approximately $2,095,000 and $4,351,100 (net of commissions paid to Ladenburg of approximately $65,500 and $135,700 and legal fees), respectively, pursuant to the Sales Agreement. Further, during 2023 and 2024, we implemented reductions in our workforce and eliminated 19 full-time equivalent positions. These cost reduction actions were intended to preserve cash, as we kept capital expenditures to minimum levels in order to reduce operating costs and our short-term cash needs.
What changed in the latest 10-Q
Risk Factors
New heading “The issuance and sale of our common stock to Roth Principal Investments may cause dilution to our other stockholders and the sale of the shares of common stock acquired by Roth Principal Investments, or the perception that such sales may occur, could cause the price of our common stock to decrease.”
Removed heading “We discontinued the production of our memory products.”
Largest changes
“On July 21, 2026, we received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of our common stock for the 30 consecutive business days ending on July 20, 2026, we no longer met the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have been provided a period of 180 calendar days, or until January 19, 2027, in which to regain compliance. …”see in full comparison
“The issuance and sale of our common stock to Roth Principal Investments may cause dilution to our other stockholders and the sale of the shares of common stock acquired by Roth Principal Investments, or the perception that such sales may occur, could cause the price of our common stock to decrease.”see in full comparison
“Our common stock may lose value and could be delisted from Nasdaq due to several factors or a combination of such factors. While our common stock is currently listed on Nasdaq, we can give no assurance that we will be able to maintain compliance with the continued listing requirements of Nasdaq, including, but not limited to, the corporate governance requirements and the minimum closing bid price requirement or the minimum equity requirement. …”see in full comparison
“There can be no assurance that we will be able to regain compliance with the minimum bid price requirement and other continued listing requirements of Nasdaq, and our common stock could be delisted in the future.”see in full comparison
“On June 30, 2026, we entered into the Purchase Agreement with Roth Principal Investments, pursuant to which Roth Principal Investments has committed to purchase up to $25.0 million of shares of our common stock, upon the terms and subject to the conditions set forth in the Purchase Agreement. …”see in full comparison
Full comparison: every changed paragraph (15)
Our condensed consolidated financial statements as of MarchJune 31,30, 2026
have been prepared under the assumption that we will continue as a going concern for the next twelve months. As of MarchJune 31,30, 2026, we
had cash and cash equivalents of $2.7$3.3 million and an accumulated deficit of $184.4$186.6 million. We believe that our existing cash and cash
equivalents as of MarchJune 31,30, 2026 and expected receipts associated with forecasted product sales will enable us to meet our capital needs
into the fourth quarter of 2026. This estimate does not assume any further sales under the Sales Agreement or the Purchase Agreement with Roth Principal Investments, both of which remain available to us, at our discretion, as potential additional sources of capital, subject to compliance with the terms and conditions of each agreement, as applicable.
We incurred net losses of approximately
$2.5 $4.7 million for the threesix months ended MarchJune 31,30, 2026 and $4.8 million for the year ended December 31, 2025, and we had an accumulated
deficit of approximately $184.4$186.6 million as of MarchJune 31,30, 2026. These and prior-year losses have resulted in significant negative cash
flows. To remain competitive and expand our product offerings to customers, we will need to increase revenues substantially beyond levels
that we have attained in the past in order to generate sustainable operating profit and sufficient cash flows to continue doing business
without raising additional capital from time to time. Given our history of fluctuating revenues and operating losses, and the challenges
we face in securing customers for our products, we cannot be certain that we will be able to achieve and maintain profitability on either
a quarterly or annual basis in the future. As a result, we may need to raise additional capital in the future, which may or may not be
available to us at all or only on unfavorable terms.
The issuance and sale of our common stock to Roth Principal Investments may cause dilution to our other stockholders and the sale of the shares of common stock acquired by Roth Principal Investments, or the perception that such sales may occur, could cause the price of our common stock to decrease.
On June 30, 2026, we entered into the Purchase Agreement with Roth Principal Investments, pursuant to which Roth Principal Investments has committed to purchase up to $25.0 million of shares of our common stock, upon the terms and subject to the conditions set forth in the Purchase Agreement. The shares of our common stock that may be issued under the Purchase Agreement may be sold by us to Roth Principal Investments at our discretion from time to time over a 36-month period following the effective date of the registration statement registering the resale of such shares, subject to certain conditions. The purchase price for the shares that we may sell to Roth Principal Investments under the Purchase Agreement will fluctuate based on the market price of our common stock. Depending on demand and market liquidity at the time, sales of such shares by Roth Principal Investments may cause the trading price of our common stock to decrease.
We have the right to control the timing and amount of any future sales of our shares to Roth Principal Investments, subject to certain limitations set forth in the Purchase Agreement. Any sales of our common stock to Roth Principal Investments will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to Roth Principal Investments all, some or none of the shares of our common stock that may be available for us to sell pursuant to the Purchase Agreement. If and when we sell shares to Roth Principal Investments, Roth Principal Investments may then resell all, some or none of those shares at any time or from time to time in its discretion. Therefore, our sales to Roth Principal Investments could result in substantial dilution to the interests of other holders of our common stock. Additionally, the sale of a substantial number of shares of our common stock to Roth Principal Investments, or the anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales.
The Purchase Agreement includes the Exchange Cap on the number of shares issuable to Roth Principal Investments, representing 19.99% of our shares of common stock outstanding immediately prior to execution of the Purchase Agreement. The Exchange Cap will not apply if either (i) we obtain stockholder approval to issue shares in excess of the Exchange Cap or (ii) the average price per share paid by Roth Principal Investments for all shares purchased under the Purchase Agreement equals or exceeds $0.9853, in each case in accordance with Nasdaq Listing Rule 5635(d). We intend to seek stockholder approval to remove the Exchange Cap, which, if obtained, would permit us to issue a substantially greater number of shares to Roth Principal Investments than would otherwise be permitted at a lower price per share, resulting in materially greater dilution to our stockholders than described above.
Our evaluation of strategic alternatives,
including Mobix Labs’ proposal,alternatives may not lead to a favorable outcome and could create business disruption and stock price volatility.
In July 2025, our board of directors authorized the exploration of strategic alternatives, including a merger, sale of assets or other similar transaction, all intended to maximize stockholder value and further our business operations. We engaged an investment bank to assist with the exploration process.
On June 27, 2025, we confirmed
in a public press release the receipt of an unsolicited non-binding acquisition proposal from Mobix Labs, which initial proposal was subsequently
revised by Mobix Labs, most recently on October 3, 2025. On July 11, 2025, we announced that our Board has authorized the exploration
of strategic alternatives, including a merger, sale of assets or other similar transaction, all intended to maximize stockholder value
and further our business operations. This process is ongoing, and our Board has not set a definitive timetable for the completion of its
evaluation. In connection with our ongoing strategic review process, the Board is evaluating Mobix Labs’ revised unsolicited non-binding
proposal to acquire all of our outstanding shares for $1.30 per share in cash, which we received from Mobix Labs on October 3, 2025, and
on October 30, 2025, we entered into a mutual confidentiality agreement with Mobix Labs, which contains customary terms, including mutual
12-month standstill and non-solicitation provisions.
The process of reviewing potential
strategic alternatives has been and may continue to be a significant distraction for our Boardboard of directors and management, and has required and may
continue to require the expenditure of significant time and resources by us, which may cause concern to our employees, investors, strategic
partners, and other constituencies and may have a material impact on our business and operating results and/or result in increased volatility
in our share price.
On July 21, 2026, we received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of our common stock for the 30 consecutive business days ending on July 20, 2026, we no longer met the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have been provided a period of 180 calendar days, or until January 19, 2027, in which to regain compliance. In order to regain compliance with the minimum bid price requirement, the closing bid price of our common stock must be at least $1 per share for a minimum of ten consecutive business days during this 180-day period. In the event we do not regain compliance within this 180-day period, we may be eligible to seek an additional compliance period of 180 calendar days provided we meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for Nasdaq, with the exception of the bid price requirement, and further provide written notice to Nasdaq of our intent to cure the deficiency during this second compliance period by effecting a reverse stock split, if necessary. However, if it appears to the Nasdaq staff that we will not be able to cure the deficiency, or if we are otherwise not eligible, Nasdaq will provide notice to us that our common stock will be subject to delisting.
There can be no assurance that we will be able to regain compliance with the minimum bid price requirement and other continued listing requirements of Nasdaq, and our common stock could be delisted in the future.
Our common stock may lose value and could be delisted from Nasdaq due to several factors or a combination of such factors. While our common stock is currently listed on Nasdaq, we can give no assurance that we will be able to maintain compliance with the continued listing requirements of Nasdaq, including, but not limited to, the corporate governance requirements and the minimum closing bid price requirement or the minimum equity requirement. If we fail to maintain compliance with any such continued listing requirement, there can also be no assurance that we will be able to regain compliance with any such continued listing requirement in the future or that our common stock will not be delisted in the future.
We discontinued the production of our memory
products.
Taiwan Semiconductor Manufacturing
Corporation, or TSMC, the sole foundry that manufactured the wafers used to produce our memory IC products, discontinued the foundry process
used to produce such wafers. As a result, we commenced an end-of-life (“EOL”) of our memory products in 2023. We expect revenues
from sales of our memory IC products to be minimal during 2026. The discontinuation of the production and sale of our memory IC products
will negatively impact our future revenues, results of operations and cash flows.
Management's Discussion & Analysis (MD&A)
New heading “Strategic Initiatives”
New heading “Committed Equity Facility”
Removed heading “Unsolicited, Non-binding Proposal from Mobix Labs, Inc.; Strategic Review Process”
Largest changes
“Unsolicited, Non-binding Proposal from Mobix Labs, Inc.; Strategic Review Process”see in full comparison
“On June 30, 2026, we entered into a Common Stock Purchase Agreement, as amended by a letter agreement dated July 10, 2026 (as amended, the “Purchase Agreement”), and a related Registration Rights Agreement with Roth Principal Investments, LLC (“Roth Principal Investments”), pursuant to which Roth Principal Investments has committed to purchase up to $25.0 million of shares of our common stock from time to time, at our discretion, over a 36-month period, subject to the terms and conditions set forth in the Purchase Agreement. …”see in full comparison
“On September 8, 2025, we issued a press release providing another update on our strategic review process, including regarding the two letters that we received from Mobix Labs, dated as of September 4, 2025, and September 5, 2025, in connection with its unsolicited offer to acquire all outstanding shares of the Company. The September 4 letter included a revised acquisition proposal involving a combination of cash and stock consideration in an undetermined amount, and a reiteration of Mobix Labs’ refusal to enter into a confidentiality agreement or receive MNPI from us. …”see in full comparison
On August 30, 2024, we entered into an At The Market Offering Agreement (the “Sales Agreement”) with Ladenburg Thalmann & Co. Inc. (“Ladenburg”) with respect to an “at the market” offering program, under which we may, from time to time, in our sole discretion, issue and sell through Ladenburg, acting as agent or principal, shares of our common stock. The Sales Agreement provides that Ladenburg will be entitled to compensation for its services equal to 3.0% of the gross proceeds from sales of any shares of common stock pursuant to the Sales Agreement in addition to the reimbursement of certain expenses. We have no obligation to sell any shares pursuant to the Sales Agreement and either we or Ladenburg may terminate the Sales Agreement in accordance with its terms.see in full comparisonDuring the twelve months ended December 31, 2025 and 2024, we sold 3,713,939 and 251,621 shares, respectively, of common stock for net proceeds of approximately $4,351,100 and $336,000, respectively, pursuant to the Sales Agreement. During the three months ended March 31, 2026, we sold 2,371,943 shares of common stock for net proceeds of approximately $2,303,484 pursuant to the Sales Agreement. Subsequent to March 31, 2026, we have sold 2,104,742 shares of common stock for net proceeds of approximately $2,061,205 through May 12, 2026. We currently have no amounts registered for sale under the Sales Agreement. We intend to file a new prospectus supplement under our existing shelf registration statement on Form S-3 following the filing of this Quarterly Report on Form 10-Q to register additional shares of common stock for sale under the Sales Agreement. The amount available for sale under any such prospectus supplement will be subject to limitations under General Instruction I.B.6 of Form S-3, which limits the aggregate market value of securities that may be sold by us during any 12-month period, as well as market conditions and other factors.
Full comparison: every changed paragraph (46)
Our integrated mmWave solutions provide secure, low-latency, high-capacity connectivity for applications spanning fixed wireless access, defense, public safety, mobility, industrial networking, and autonomous systems. In recent quarters, we have been focused on addressing market opportunities for the rapidly expanding requirements of unmanned aerial vehicles (“UAV”), including drones, autonomous systems, and defense communications applications. In 2025, we secured our first defense application with a customer for a drone identification friend or foe (“IFF”) system designed to operate in highly contested electronic warfare environments. Since then, we have expanded our initial engagement with this customer for an IFF application for personnel-mounted systems to IFF applications for our module products for drones. We have also been engaged with another customer for applications for autonomous vehicles and drone swarms. We believe the autonomous, UAV and defense communications markets represent a significant market opportunity for us.
We also had a memory product
line comprising our Bandwidth Engine IC products. Taiwan Semiconductor Manufacturing Corporation, or TSMC, the sole foundry that manufactured
the wafers used to produce our memory IC products, discontinued the foundry process used to produce such wafers. As a result, in May 2023,
we initiated an end-of-life, or EOL, of our memory IC products, and, in March 2025, we fulfilled all then-outstanding EOL orders for our
memory IC products. Subsequent to March 2025, we received additional purchase orders and recorded revenue totaling approximately $0.5
million duringIn the second half of 2025. During the three months ended March 31, 2026,2025, we receivedfulfilled an additionaltwo purchase orderorders andfor recorded
revenue totaling approximately $20,000.$0.5 million. During the six months ended June 30, 2026, we fulfilled two additional purchase orders for revenue totaling approximately $27,000.
We incurred net losses of approximately
$2.5 $4.7 million for the threesix months ended MarchJune 31,30, 2026 and $4.8 million for the year ended December 31, 2025, and we had an accumulated
deficit of approximately $184.4$186.6 million as of MarchJune 31,30, 2026. These and prior year losses have resulted in significant negative
cash flows and historically have required us to raise substantial amounts of additional capital. As discussed below, this raises significant
doubt about our ability to continue as a going concern. We will need to increase revenues substantially beyond levels that we have attained
in the past in order to generate sustainable operating profit and sufficient cash flows to continue doing business without raising additional
capital from time to time.
Strategic Initiatives
We received an unsolicited, non-binding proposal from Mobix Labs, Inc.(“Mobix”) to acquire the Company, as described in our Annual Report on Form 10-K for the year ended December 31, 2025 and Current Report on Form 8-K filed with the SEC on January 21, 2026. There have been no further developments since that time. As initially disclosed in July 2025, our board of directors authorized the exploration of strategic alternatives, including a merger, sale of assets or other similar transaction, all intended to maximize stockholder value and further our business operations. There can be no assurance that any transaction will result from our evaluation of strategic alternatives.
Unsolicited, Non-binding Proposal from Mobix
Labs, Inc.; Strategic Review Process
On June 27, 2025, we confirmed
in a public press release the receipt of an unsolicited, non-binding proposal from Mobix Labs, Inc. (“Mobix Labs”) to acquire
all of the Company’s issued and outstanding equity securities in exchange for newly issued shares of Mobix Labs common stock, with
a fixed exchange ratio based on the average daily closing price of our common stock over the 30 calendar days ending on June 11, 2025,
plus a 20% premium, or approximately $1.20 per share.
On July 11, 2025, we issued
a press release announcing the initiation of the strategic review process. Following this, our financial advisor contacted potential counterparties
to invite them to participate in the process subject to such parties’ execution of our standard non-disclosure agreement, which
includes a standstill provision. Our financial advisor also contacted Mobix Labs to request that Mobix Labs execute our non-disclosure
agreement in order to participate in the process, which Mobix Labs declined to execute.
On August 19, 2025, we issued
a public press release providing an update on our strategic review process, including our engagement with potential counterparties and
our continued openness to engaging with Mobix Labs and others, while noting that Mobix Labs declined to enter into our standard non-disclosure
agreement and indicated it would not agree to receive material non-public information (“MNPI”).
On September 8, 2025, we issued
a press release providing another update on our strategic review process, including regarding the two letters that we received from Mobix
Labs, dated as of September 4, 2025, and September 5, 2025, in connection with its unsolicited offer to acquire all outstanding shares
of the Company. The September 4 letter included a revised acquisition proposal involving a combination of cash and stock consideration
in an undetermined amount, and a reiteration of Mobix Labs’ refusal to enter into a confidentiality agreement or receive MNPI from
us. The September 5 follow-up letter stated that while Mobix Labs continued to oppose any standstill restrictions, it would be willing
to consider a limited confidentiality arrangement to permit us to share MNPI deemed reasonably necessary, provided that such arrangement
did not include a standstill and did not indefinitely constrain Mobix Labs. In response to such letters, we authorized a limited exploratory
call with Mobix Labs, and we requested that any such discussion take place without us sharing any MNPI and outside the bounds of a confidentiality
agreement, which exploratory call would serve to allow us to better understand Mobix Labs’ revised proposal and intentions.
On September 11, 2025, following
the limited exploratory call with Mobix Labs on September 10, 2025, Mobix Labs issued a public statement describing the discussions had
in such limited exploratory call and announcing an enhanced proposal of approximately 30% cash and 70% Mobix Labs common stock. Then,
on September 12, 2025, we issued a press release to provide clarification to all stockholders relating to such public statements made
by Mobix Labs, including that we did not respond to Mobix Labs’ proposal and that we did not agree to continue discussions with
Mobix Labs during the call, and we sent a letter to Mobix Labs to clarify our position.
On September 13, 2025, Mobix
Labs filed a Form 425 with the SEC and issued a related press release announcing its intent to commence a hostile exchange offer to acquire
all outstanding shares of the Company. In the press release, Mobix Labs stated that the proposed offer is expected to consist of a mix
of cash and Mobix Labs common stock, with an intended closing timeline of approximately 75 days.
On September 29, 2025, Mobix
Labs delivered another letter to our board of directors reiterating its interest in a business combination and submitting what it described
as a definitive proposal to acquire all outstanding shares of the Company for $1.30 per share, consisting of a mix of cash and Mobix Labs
common stock, and also separately requested our cooperation with respect to an anticipated registration statement on Form S-4.
On October 3, 2025, Mobix
Labs delivered an updated letter superseding its prior proposal and proposing to acquire all outstanding shares of the Company for $1.30
per share in cash, stating that the proposal was not subject to financing contingencies and was based on our publicly reported share count
as of June 30, 2025.
On October 6, 2025, we sent
a letter to Mobix Labs acknowledging receipt of its revised proposal and requesting clarification regarding share count assumptions, treatment
of the Company’s publicly disclosed warrants and equity-linked instruments, and financing sources. Also on October 6, 2025, Mobix
Labs issued a press release publicly announcing its updated all-cash proposal and reiterating its preference for a cooperative process
with the Company.
On October 30, 2025, we entered
into a mutual confidentiality agreement with Mobix Labs in connection with our ongoing review of strategic alternatives. The confidentiality
agreement contains customary terms, including mutual 12-month standstill and non-solicitation provisions. On November 3, 2025, Mobix Labs
issued a press release publicly announcing its entry into a mutual confidentiality agreement with us.
On January 21, 2026, Mobix
Labs issued a press release, and we filed a Current Report on Form 8-K disclosing that the Company and Mobix Labs continue to engage in
discussions regarding a potential strategic transaction and are conducting customary, confidential diligence and that Mobix Labs delivered
to the Company a non-binding indication of interest contemplating a potential all-stock transaction at a premium to the Company’s
trading price, subject to further diligence, negotiation, and the execution of definitive documentation.
Our board of directors continues
to evaluate the Company’s options to enhance stockholder value. Our board of directors and management team are committed to acting
in the best interests of all stockholders. Consistent with its fiduciary duties and in consultation with the Company’s financial
and legal advisors, our board of directors will continue to carefully review Mobix Labs’ proposal to determine the course of action
that it believes is in the best interest of the Company and its stockholders. We do not intend to make further comments regarding potential
transactions or provide any public updates regarding proposed or potential transactions, unless required by applicable law or a regulatory
body. There can be no assurance that any transaction will be completed with Mobix Labs or any other third party.
On August 30, 2024, we entered
into an At The Market Offering Agreement (the “Sales Agreement”) with Ladenburg Thalmann & Co. Inc. (“Ladenburg”)
with respect to an “at the market” offering program, under which we may, from time to time, in our sole discretion, issue
and sell through Ladenburg, acting as agent or principal, shares of our common stock. The Sales Agreement provides that Ladenburg will
be entitled to compensation for its services equal to 3.0% of the gross proceeds from sales of any shares of common stock pursuant to
the Sales Agreement in addition to the reimbursement of certain expenses. We have no obligation to sell any shares pursuant to the Sales
Agreement and either we or Ladenburg may terminate the Sales Agreement in accordance with its terms. During the twelve months ended December
31, 2025 and 2024, we sold 3,713,939 and 251,621 shares, respectively, of common stock for net proceeds of approximately $4,351,100 and
$336,000, respectively, pursuant to the Sales Agreement. During the three months ended March 31, 2026, we sold 2,371,943 shares of common
stock for net proceeds of approximately $2,303,484 pursuant to the Sales Agreement. Subsequent to March 31, 2026, we have sold 2,104,742
shares of common stock for net proceeds of approximately $2,061,205 through May 12, 2026. We currently have no amounts registered for
sale under the Sales Agreement. We intend to file a new prospectus supplement under our existing shelf registration statement
on Form S-3 following the filing of this Quarterly Report on Form 10-Q to register additional shares of common stock for sale under the
Sales Agreement. The amount available for sale under any such prospectus supplement will be subject to limitations under General Instruction
I.B.6 of Form S-3, which limits the aggregate market value of securities that may be sold by us during any 12-month period, as well as
market conditions and other factors.
During the three months ended June 30, 2026, we sold 2,449,681 shares of common stock for net proceeds of approximately $2,364,376 (net of commissions paid to Ladenburg of approximately $73,591) pursuant to the Sales Agreement. Subsequent to June 30, 2026, we sold 23,797 shares of common stock for net proceeds of approximately $20,901 pursuant Sales Agreement. See Note 7 to the condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information regarding the terms of the Sales Agreement.
Committed Equity Facility
On June 30, 2026, we entered into a Common Stock Purchase Agreement, as amended by a letter agreement dated July 10, 2026 (as amended, the “Purchase Agreement”), and a related Registration Rights Agreement with Roth Principal Investments, LLC (“Roth Principal Investments”), pursuant to which Roth Principal Investments has committed to purchase up to $25.0 million of shares of our common stock from time to time, at our discretion, over a 36-month period, subject to the terms and conditions set forth in the Purchase Agreement. The Purchase Agreement includes an exchange cap of 3,004,114 shares (the “Exchange Cap”) on the number of shares issuable to Roth Principal Investments, representing 19.99% of our shares of common stock outstanding immediately prior to execution of the Purchase Agreement. The Exchange Cap will not apply if either (i) we obtain stockholder approval to issue shares in excess of the Exchange Cap or (ii) the average price per share paid by Roth Principal Investments for all shares purchased under the Purchase Agreement equals or exceeds $0.9853, in each case in accordance with Nasdaq Listing Rule 5635(d). We intend to seek stockholder approval to remove the Exchange Cap. We are under no obligation to sell any shares under the Purchase Agreement. The registration statement registering the resale of shares issuable under the Purchase Agreement was declared effective by the SEC on July 14, 2026. See Note 7 to the condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q for additional information regarding the terms of the Purchase Agreement.
The discussion and analysis
of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared
in accordance with accounting principles generally accepted in the United States (GAAP). The preparation of these condensed consolidated
financial statements requires us to make certain estimates and judgments that affect the reported amounts of assets, liabilities, revenues
and expenses. On an ongoing basis we make these estimates based on our historical experience and on assumptions that we consider reasonable
under the circumstances. Actual results may differ from these estimates and reported results could differ under different assumptions
or conditions. Our significant accounting policies and estimates are disclosed in Note 1 of the “Notes to Condensed Consolidated
Financial Statements” included in Part I, Item 1 of this Quarterly Report on Form 10-Q and Note 1 of the “Notes
to Consolidated Financial Statements” in our Annual Report on Form 10-K for the year ended December 31, 2025. As of March
31,June 30, 2026, there have been no material changes to our significant accounting policies and estimates.
The following tabletables details
revenue by product category for the three and six months ended MarchJune 31,30, 2026 and 2025:
Product revenue decreased for the three and six months ended MarchJune 31,30, 2026
compared with the same period of 2025 primarily due to the decrease in sales of our EOL memory IC products dueand to the significanta decrease
in EOL shipments and decreases in shipments of our mmWave ICs and antenna modules. The decline in mmWave product shipments during the
three six months ended MarchJune 31,30, 2026 alsowas reflected the delayed shipment of a sizable order dueattributed to material availability constraints from
one of our suppliers, as well as subdued near-term demand from existing fixed wireless access customers. The delayed order was shipped
subsequent to March 31, 2026.
Services and other revenue
includes royalty, non-recurring engineering services and license revenues. The increase in services and other revenue for the three and six months
ended MarchJune 31,30, 2026 compared with the same period of 2025 was primarily due to an increase in non-recurring engineering services revenue
related to our mmWave technology, partially offset by a decrease in royalties from licensees of our memory technology due to reduced shipments
by these licensees, which we attribute to the discontinuation of the foundry process by TSMC.
Cost of net revenue decreased
for the three and six months ended MarchJune 31,30, 2026 when compared with the same periodperiods inof 2025, primarily relateddue to the decreasecorresponding decreases in product revenue.
Gross profit decreased for the three months ended MarchJune 31,30, 2026 compared
with the same period of 2025, primarily due to the reduction in product revenues, partially offset by increased services and other revenues.
During the three months ended MarchJune 31,30, 2026 and 2025, we sold mmWave inventory with cost of net revenue values of approximately $182,000$0.3 million and $94,000,$0.2 million, respectively,
which was written down prior to January 1, 2026,2026. Gross profit decreased for the six months ended June 30, 2026 compared with the same period of 2025, primarily due to the reduction in product revenues combined with product mix, specifically the decrease in memory IC shipments. The decrease was partially offset by the net increase in services and other revenues. During the six months ended June 30, 2026 and 2025, we sold tommWave customers.inventory with cost of net revenue values of approximately $0.5 million and $0.3 million, respectively.
We expect that total R&D
expenses will remain flat for the remainder of 2026 compared with the priorfirst periodssix months of 2025.2026.
The slight increase for the three months ended June 30, 2026 compared with the same period of 2025 was primarily attributable to increases in consulting and professional services costs. The decrease for the three
six months ended MarchJune 31,30, 2026 compared with the same period of 2025 was primarily attributable to reductions in expenses for facilities
and stock based compensation. These decreases were partially offset by increases in consulting and professional services costs. We expect
that total SG&A expense will remain flat or slightly decrease for the remainder of 2026 compared with 2025, as we continue to manage
our SG&A expenses.
We expect that total SG&A expense will remain flat or slightly decrease for the remainder of 2026 compared with 2025, as we continue to manage our SG&A expenses.
As of MarchJune 31,30, 2026, we had
cash and cash equivalents of $2.7$3.3 million and working capital of $4.0 million.
Net cash used in operating
activities was $2.3 million for the first three months of 2026, which primarily resulted from our net loss of $2.5 million, as partially
offset by non-cash charges of $0.1 million of depreciation and amortization and $0.1 million of stock based compensation.
Net cash used in operating
activities was $1.0$3.9 million for the first threesix months of 2025,2026, which primarily resulted from our net loss of $0.5$4.7 million, as adjusted
for cash outflows of $0.7 million in net changes in assets and liabilities, and partially offset by non-cash charges of $0.1 million of
depreciation and amortization and $0.1$0.3 million of stock based compensation.compensation, and $0.4 million in net changes in assets and liabilities. The changes in assets and liabilities primarily related to
the timing of collections of receivables, purchases of inventory and other vendor payables and prepayments.
Net cash used in operating activities was $3.0 million for the first six months of 2025, which primarily resulted from our net loss of $2.3 million, as adjusted for $1.1 million in net changes in assets and liabilities, as partially offset by non-cash charges of $0.1 million of depreciation and amortization and $0.3 million of stock based compensation. The changes in assets and liabilities primarily related to the timing of collections of receivables, purchases of inventory and other vendor payables and prepayments.
Net cash used in investing
activities ofwas approximately $0.2$0.3 million for the threefirst six months endedof March 31, 20262026, which was attributable to the purchase of fixed assets.
Net cash used in investing activities was approximately $45,000 for the first six months of 2025, which was attributable to the purchase of fixed assets.
For the three months ended
March 31, 2025 no cash was provided by or used in investing activities.
Net cash provided by financing
activities of $2.3 million for the three months ended March 31, 2026 primarily comprised $2.3 million of net proceeds from sales of our
common stock under the Sales Agreement.
Net cash provided by financing
activities for the threesix months ended MarchJune 31,30, 20252026 comprised $0.4$4.7 million of net proceeds from sales ofunder our commonat-the stockmarket underoffering the Sales
Agreement,program, partially offset by repaymentapproximately $0.1 million of financingpayments leaserelated liabilities.to costs associated with our committed equity facility and proceeds from option exercises.
Net cash provided by financing activities for the six months ended June 30, 2025 comprised $1.5 million of net proceeds from sales under our at-the market offering program, partially offset by repayment of financing lease liabilities.
Our primary purchase obligations
include non-cancelable purchase orders for inventory. At MarchJune 31,30, 2026, we had outstanding non-cancelable purchase orders for inventory,
primarily wafers and substrates, and related expenditures of approximately $3.2$2.4 million.
We incurred net losses of
approximately $2.5$4.7 million for the threesix months ended MarchJune 31,30, 2026 and $4.8 million for the year ended December 31, 2025, and we had
an accumulated deficit of approximately $184.4$186.6 million as of MarchJune 31,30, 2026. These and prior year losses have resulted in significant
negative cash flows and have required us to raise substantial amounts of additional capital. To date, we have primarily financed our operations
through loans, offerings of common stock and warrants and issuances of convertible notes.
We expect to continue to incur
operating losses during 2026, as we do not expect to generate any meaningful revenue from shipments of our remaining memory products and
as we continue to secure new customers for and continue to invest in the development of our mmWave products. Further, we expect our cash
expenditures to continue to exceed receipts for at least the next 12 months, as our revenues will not be sufficient to offset our operating
expenses. In addition, we have incurred and may continue to incur substantial costs related to our strategic alternative exploration process,
which costs include the fees of our financial and legal advisors. We believe that our existing cash and cash equivalents as of MarchJune 31,
30, 2026 and expected receipts associated with forecasted product sales will enable us to meet our capital needs into the fourth quarter of
2026. This estimate does not assume any further sales under the Sales Agreement or the Purchase Agreement with Roth Principal Investments, both of which remain available to us, at our discretion, as potential additional sources of capital, subject to compliance with the terms and conditions of each agreement, as applicable.
We will need to increase revenues
beyond the levels that we have attained in the past in order to generate sustainable operating profit and sufficient cash flows to continue
doing business without raising additional capital from time to time. As a result of our expected operating losses and cash burn and recurring
losses from operations, if we are unable to raise sufficient capital through additional debt or equity arrangements, there will be uncertainty
regarding our ability to maintain liquidity sufficient to operate our business effectively, which raises substantial doubt as to our ability
to continue as a going concern within one year from the date of issuance of our condensed consolidated financial statements. In addition,
our independent registered public accounting firm, in its report on our consolidated financial statements for the year ended December
31, 2025, expressed substantial doubt about our ability to continue as a going concern. The condensed consolidated financial statements
presented in Part I, Item 1 of this Quarterly Report on Form 10-Q have been prepared assuming that we will continue as a going concern,
and do not include any adjustments that might result from the outcome of this uncertainty. There can be no assurance that such additional
capital, whether in the form of debt or equity financing, will be sufficient or available and, if available, that such capital will be
offered on terms and conditions acceptable to us. We aremay currently sellingsell shares of our common stock under the Sales AgreementAgreement, and may sell shares of our common stock under the Purchase Agreement with Roth Principal Investments, in each case from time to time and at our discretion, and we are seeking
additional financing in order to meet our cash requirements for the foreseeable future. If we are unsuccessful in these efforts, we will
need to implement additional cost reduction strategies, which could further affect our near- and long-term business plan. These cost reduction
strategies may include, but are not limited to, reducing headcount and curtailing business activities.
In the ordinary course of
business, we enter into contractual arrangements under which we may agree to indemnify the counter-party from losses relating to a breach
of representations and warranties, a failure to perform certain covenants, or claims and losses arising from certain external events as
outlined within the contract, which may include, for example, losses arising from litigation or claims relating to past performance. Such
indemnification clauses may not be subject to maximum loss clauses. We have also entered into indemnification agreements with our officers
and directors. No material amounts related to these indemnifications are reflected in our condensed consolidated financial statements
for the threesix months ended MarchJune 31,30, 2026.
PRSO insider buying and selling (Form 4)
Since 2026-04-11, insiders reported open-market purchases in 0 Form 4 filings and open-market sales in 0 filings. Totals add up every open-market (code P and S) line in those filings, using the prices reported in the filings. Awards, option exercises, tax withholding and gifts are listed below but not counted.
No Form 4 stock transactions in this period.
Well-known investors holding PRSO (13F)
None of the 59 investors we track reported a position in their latest 13F.